Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385121 | 0.80 | TSHR (0.48) | CYP19A1TSHRNPSR1KDM4ELMNA | |
| SCHEMBL27303553 | 0.72 | CYP19A1 (0.52) | CYP19A1TSHRNPSR1 | |
| SCHEMBL6077915 | 0.72 | CYP19A1 (0.51) | CYP19A1TSHRNPSR1 | |
| SCHEMBL10671373 | 0.71 | CYP19A1 (0.44) | CYP19A1KDM4ELMNACYP2C19 | |
| SCHEMBL3201760 | 0.70 | CYP19A1 (0.48) | CYP19A1TSHRNPSR1 | |
| SCHEMBL27666457 | 0.69 | CYP19A1 (0.49) | CYP19A1TSHRNPSR1KDM4ELMNA | |
| SCHEMBL5690991 | 0.67 | CYP19A1 (0.49) | CYP19A1TSHRNPSR1KDM4ELMNA | |
| SCHEMBL27637547 | 0.67 | CYP19A1 (0.42) | CYP19A1TSHRNPSR1KDM4ECYP2C19 | |
| SCHEMBL18529897 | 0.67 | CYP19A1 (0.44) | CYP19A1TSHRNPSR1KDM4ELMNA | |
| SCHEMBL3471819 | 0.66 | TSHR (0.48) | CYP19A1TSHRNPSR1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012020080-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | CYP19A1 4585/4885TSHR 1085/4885NPSR1 1721/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | CYP19A1 947/4885TSHR 173/4885NPSR1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.